[{"id":"d5620614-b21c-4e48-b7e1-c4792175d95e","acronym":"APEX-01","url":"https://clinicaltrials.gov/study/NCT04662580","created_at":"2023-11-22T19:16:10.387Z","updated_at":"2024-07-02T16:35:04.424Z","phase":"Phase 1","brief_title":"ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04662580 - APEX-01","lead_sponsor":"Ambrx, Inc.","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • JNJ-8177"],"overall_status":"Recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 07/27/2021","start_date":" 07/27/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-05-10"}]